Social Anxiety Disorder (SAD)

Neurology·MeSH: Phobia, Social

Prevalence

6090.6 / 100K

Incidence

716.2 / 100K/yr

7 drugs in development·7 companies·3 clinical trials

Drug Pipeline by Phase

Approved(2)

Drug	Company
paroxetine	Mylan II B.V. (MYL)
paroxetine	OXFORD IMMUNOTEC GLOBAL PLC (OXFD)

Phase 3(3)

Drug	Company
bnc210	Neuphoria Therapeutics Inc. (NEUP)
fasedienol	Vistagen Therapeutics, Inc. (VTGN)
vqw-765	Vanda Pharmaceuticals Inc. (VNDA)

Phase 2(2)

Drug	Company
EMP-01	Atai Beckley N.V. (ATAI)
ENX-102	Valneva SE (VALN)

BioSniper tracks 7 drugs in development for Social Anxiety Disorder (SAD) across 7 companies.

There are 3 clinical trials targeting Social Anxiety Disorder (SAD) tracked by BioSniper.

The estimated prevalence of Social Anxiety Disorder (SAD) is approximately 6090.6 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.